Excelsior Biopharma Inc. (TPEX:6496)
Taiwan · Delayed Price · Currency is TWD 28.85
+0.05 (0.17%)
Jan 22, 2026, 1:30 PM CST
Excelsior Biopharma Revenue
Excelsior Biopharma had revenue of 207.15M TWD in the quarter ending September 30, 2025, a decrease of -5.06%. This brings the company's revenue in the last twelve months to 859.77M, up 3.54% year-over-year. In the year 2024, Excelsior Biopharma had annual revenue of 861.91M with 11.71% growth.
Revenue (ttm)
859.77M
Revenue Growth
+3.54%
P/S Ratio
1.57
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.35B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 861.91M | 90.35M | 11.71% |
| Dec 31, 2023 | 771.56M | 99.80M | 14.86% |
| Dec 31, 2022 | 671.76M | -666.63M | -49.81% |
| Dec 31, 2021 | 1.34B | -105.27M | -7.29% |
| Dec 31, 2020 | 1.44B | -96.40M | -6.26% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| TSH Biopharm Corporation | 1.27B |
| Anxo Pharmaceutical | 883.22M |
| Prince Pharmaceutical | 798.27M |
| Winston Medical Supply | 724.35M |
| DV Biomed | 712.61M |
| GeneFerm Biotechnology | 654.88M |
| Tien Liang BioTech | 467.02M |
| Mediera | 240.30M |